Cullinan Therapeutics, Inc.
CGEM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789972
In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $1.30B in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Cullinan Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 100
- +11 vs. Q2 2022
- Shares held
- 37.0M
- −551.3K (−1.5%) vs. Q2 2022
- Total value
- $474.7M
- −$7.05M (−1.5%) vs. Q2 2022
- New holders
- 18
- 38 more added
- Sold out
- 7
- 29 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CGEM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 183 | $1.30B |
| Q1 2026 | 174 | $931.0M |
| Q4 2025 | 153 | $653.8M |
| Q3 2025 | 145 | $362.2M |
| Q2 2025 | 144 | $471.4M |
| Q1 2025 | 149 | $489.6M |
| Q4 2024 | 147 | $798.8M |
| Q3 2024 | 137 | $1.09B |
| Q2 2024 | 135 | $1.10B |
| Q1 2024 | 113 | $670.8M |
| Q4 2023 | 113 | $375.6M |
| Q3 2023 | 106 | $344.0M |
| Q2 2023 | 106 | $397.3M |
| Q1 2023 | 103 | $329.5M |
| Q4 2022 | 97 | $397.7M |
| Q3 2022 | 100 | $474.7M |
| Q2 2022 | 89 | $481.7M |
| Q1 2022 | 82 | $386.3M |
| Q4 2021 | 75 | $559.7M |
| Q3 2021 | 66 | $762.3M |
| Q2 2021 | 71 | $828.5M |
| Q1 2021 | 70 | $1.30B |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Cullinan Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Woodline Partners LP | 0 | $0 | 0.00% | −818,572−100.0% | Sold out |
| Soleus Capital Management, L.P. | 0 | $0 | 0.00% | −95,485−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −24,640−100.0% | Sold out |
| DuPont Capital Management Corp | 0 | $0 | 0.00% | −11,348−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −289−100.0% | Sold out |
| Rockefeller Capital Management L.P. | 0 | $0 | 0.00% | −221−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −46−100.0% | Sold out |